263 related articles for article (PubMed ID: 20733154)
1. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ; Yahalom J; Kewalramani T; Maragulia JC; Vanak JM; Zelenetz AD; Moskowitz CH
Blood; 2010 Dec; 116(23):4934-7. PubMed ID: 20733154
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging.
Moskowitz CH; Yahalom J; Zelenetz AD; Zhang Z; Filippa D; Teruya-Feldstein J; Kewalramani T; Moskowitz AJ; Rice RD; Maragulia J; Vanak J; Trippett T; Hamlin P; Horowitz S; Noy A; O'Connor OA; Portlock C; Straus D; Nimer SD
Br J Haematol; 2010 Mar; 148(6):890-7. PubMed ID: 20085577
[TBL] [Abstract][Full Text] [Related]
3. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.
Moskowitz AJ; Schöder H; Yahalom J; McCall SJ; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz S; Kobos R; Kumar A; Matasar M; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Shukla N; Steinherz P; Straus D; Trippett T; Younes A; Zelenetz A; Moskowitz CH
Lancet Oncol; 2015 Mar; 16(3):284-92. PubMed ID: 25683846
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ; Schöder H; Gavane S; Thoren KL; Fleisher M; Yahalom J; McCall SJ; Cadzin BR; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz SM; Kumar A; Matasar M; Ni A; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Straus D; Younes A; Zelenetz AD; Moskowitz CH
Blood; 2017 Nov; 130(20):2196-2203. PubMed ID: 28874350
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.
Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation.
Choi MK; Kang ES; Kim DW; Ko YH; Seok H; Park JH; Pyo DH; Hoon Lim D; Kim SJ; Kim WS
Int J Hematol; 2013 Sep; 98(3):346-54. PubMed ID: 23868695
[TBL] [Abstract][Full Text] [Related]
7. DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center.
Mikesch JH; Kuhlmann M; Demant A; Krug U; Thoennissen GB; Schmidt E; Kessler T; Schliemann C; Pohlen M; Mohr M; Evers G; Köhler G; Wessling J; Mesters R; Müller-Tidow C; Berdel WE; Thoennissen NH
Ann Hematol; 2013 Aug; 92(8):1041-8. PubMed ID: 23532626
[TBL] [Abstract][Full Text] [Related]
8. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
Moskowitz CH; Nimer SD; Zelenetz AD; Trippett T; Hedrick EE; Filippa DA; Louie D; Gonzales M; Walits J; Coady-Lyons N; Qin J; Frank R; Bertino JR; Goy A; Noy A; O'Brien JP; Straus D; Portlock CS; Yahalom J
Blood; 2001 Feb; 97(3):616-23. PubMed ID: 11157476
[TBL] [Abstract][Full Text] [Related]
9. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
[TBL] [Abstract][Full Text] [Related]
10. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.
Jabbour E; Hosing C; Ayers G; Nunez R; Anderlini P; Pro B; Khouri I; Younes A; Hagemeister F; Kwak L; Fayad L
Cancer; 2007 Jun; 109(12):2481-9. PubMed ID: 17497648
[TBL] [Abstract][Full Text] [Related]
11. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
[TBL] [Abstract][Full Text] [Related]
12. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma.
Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
14. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
[TBL] [Abstract][Full Text] [Related]
15. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
Moskowitz CH; Matasar MJ; Zelenetz AD; Nimer SD; Gerecitano J; Hamlin P; Horwitz S; Moskowitz AJ; Noy A; Palomba L; Perales MA; Portlock C; Straus D; Maragulia JC; Schoder H; Yahalom J
Blood; 2012 Feb; 119(7):1665-70. PubMed ID: 22184409
[TBL] [Abstract][Full Text] [Related]
16. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
[TBL] [Abstract][Full Text] [Related]
17. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.
Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL
Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis.
Kewalramani T; Zelenetz AD; Hedrick EE; Donnelly GB; Hunte S; Priovolos AC; Qin J; Lyons NC; Yahalom J; Nimer SD; Moskowitz CH
Blood; 2000 Oct; 96(7):2399-404. PubMed ID: 11001890
[TBL] [Abstract][Full Text] [Related]
19. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.
Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R
Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
